Durvalumab/Gefitinib

N/A

Report date: 2026/04/29 17:37:33

Base Information

Drug NameDurvalumab/Gefitinib
Drug Alias NameGefitinib/Durvalumab
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1Epidermal growth factor receptor erbB1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes DurvalumabGefitinib
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMedimmune
China Registration ClassN/A

Develop Information

Active CompaniesMedimmune Llc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A